Portal de recerca
Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Alama, Pilar
- Romero, Josep Lluis
- Mari, Marta
Grups d'Investigació
Abstract
STUDY QUESTION Does ovarian stimulation with highly purified (hp)-HMG protect from elevated progesterone in the follicular phase compared to recombinant FSH (r-FSH) cycles through a different regulation of follicular steroidogenesis?SUMMARY ANSWER hp-HMG enhanced the Delta 4 pathway from pregnenolone to androstenodione leading to lower serum progesterone at the end of the cycle, while r-FSH promoted the conversion of pregnenolone to progesterone causing higher follicular phase progesterone levels.WHAT IS KNOWN ALREADY Elevated progesterone in the follicular phase has been related to lower clinical outcome in fresh IVF cycles. Progesterone levels are positively correlated to ovarian response, and some studies have shown that when r-FSH alone is used for ovarian stimulation serum progesterone levels on the day of triggering are higher than when hp-HMG is given. Whether this is caused by a lower ovarian response in hp-HMG cycles or to a difference in follicular steroidogenesis in the two ovarian stimulation regimens has not been well characterizedSTUDY DESIGN, SIZE, DURATION A randomized controlled trial including 112 oocyte donors undergoing ovarian stimulation with GnRH antagonists and 225 IU/day of r-FSH (n = 56) or hp-HMG (n = 56) was carried out in a university-affiliated private infertility clinic. Subjects were recruited between October 2016 and June 2018.PARTICIPANTS/MATERIALS, SETTING, METHODS The women were aged 18-35 years with a regular menstrual cycle (25-35 days) and normal ovarian reserve (serum anti-Mullerian hormone (AMH) = 10-30 pMol/l) undergoing ovarian stimulation for oocyte donation. FSH, LH, estradiol (E2), estrone, progesterone, pregnenolone, 17-OH-progesterone, androstenodione, dehidroepiandrostenodione, and testosterone were determined on stimulation Days 1, 4, 6, and 8 and on day of triggering in serum and in follicular fluid. Samples were frozen at -20 degrees C until assay. Total exposures across the follicular phase were compared by polynomic extrapolation.MAIN RESULTS AND THE ROLE OF CHANCE Subjects in both groups were comparable in terms of age, BMI, and AMH levels. Ovarian response was also similar: 17.5 +/- 7.9 (mean +/- SD) versus 16.5 +/- 7.5 oocytes with r-FSH and hp-HMG, respectively (P = 0.49). Serum progesterone (ng/ml) on day of trigger was 0.46 +/- 0.27 in the hp-HMG group versus 0.68 +/- 0.50 in the r-FSH group (P = 0.010). Differences for progesterone were also significant on stimulation days 6 and 8. The pregnenolone: progesterone ratio was significantly increased in the r-FSH group from stimulation day 8 to the day of trigger (P = 0.019). Serum androstenodione (ng/ml) on day of trigger was 3.0 +/- 1.4 in the hp-HMG group versus 2.4 +/- 1.1 in the r-FSH group (P = 0.015). Differences in adrostenodione were also significant on stimulation Day 8. The pregnenolone:androstenodione ratio was significantly higher in the hp-HMG group (P = 0.012) on Days 6 and 8 and trigger. There were no other significant differences between groups. Follicular fluid E2, FSH, LH, dehidroepioandrostenodione, androstenodione, and testosterone were significantly higher in the hp-HMG than r-FSH group. No differences were observed for progesterone, estrone, 17-OH-progesterone, and pregnenolone in follicular fluid.LIMITATIONS, REASONS FOR CAUTION All women included in the study were young, not infertile, and had a normal BMI and a good ovarian reserve. The findings might be different in other patient subpopulations. Hormone analyses with immunoassays are subject to intra-assay variations that may influence the results.WIDER IMPLICATIONS OF THE FINDINGS Stimulation with hp-HMG may prevent progesterone elevation at the end of the follicular phase because of a different follicular steroidogenesis pathway, regardless of ovarian response. This should be considered, particularly in patients at risk of having high progesterone levels at the end of the follicular phase when a fresh embryo transfer is planned.STUDY FUNDING/COMPETING INTEREST(S) Roche Diagnostics provided unrestricted funding for all serum and follicular fluid hormone determinations. J.L.R., M.M., and A.P. have nothing to declare. E.B. has received consulting fees from Ferring, Merck, Gedeon Richter, and Roche and has participated in a research cooperation with Gedeon-Richter. In addition, the author has participated in speakers' bureau and received fees from Ferring, Gedeon Richter, Merck, and Roche. P.A. has received consulting fees from MSD and has participated in speakers' bureau and received fees from Ferring. P.A. also declares travel/meeting support from MSD. E.L. has received consulting fees from Ferring and MSD. In addition, the author has participated in a research cooperation with Gedeon-Richter. Also, the author has participated in speakers' bureau and received fees from Ferring and IBSA, as well as travel/meeting support from IBSA and Gedeon Richter. E.B., P.A., and E.L. also own stocks in IVIRMA Valencia.TRIAL REGISTRATION NUMBER NCT: NCT02738580.TRIAL REGISTER DATE 19 February 2016.DATE OF FIRST PATIENT'S ENROLMENT 03 October 2016.
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Dades de la publicació
- ISSN/ISSNe:
- 0268-1161, 1460-2350
- Tipus:
- Article
- Pàgines:
- 393-402
- PubMed:
- 38037188
- Factor d'Impacte:
- 1,993 SCImago ℠
- Quartil:
- Q1 SCImago ℠
HUMAN REPRODUCTION OXFORD UNIV PRESS
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Keywords
- progesterone; recombinant FSH/ LH; HMG; ovarian stimulation; follicle development; steroidogenesis; elevated follicular phase progesterone
Projectes associats
ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009
CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL
CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012
CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL
CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
CONTRATO POST FSE (RIO HORTEGA)
CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
CD15/00058 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2016
TRAMIENTO COMBINADO DE VITAMINA D CON AGNRH SOBRE EL CRECIMIENTO DE LOS MIOMAS UTERINOS
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
PI15/00312 . INSTITUTO DE SALUD CARLOS III . 2016
Alternativas para la Preservacion de la fertilidad en pacientes con leucemia aguda. Maduracion in vivo mediante xenotransplante.
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
GRISOLIAP/2018/029 . CONSELLERIA DE EDUCACION . 2018
Estudio Piloto: Evaluación del sistema CRISPR/Cas9 en la edición de ADN espermático.
Investigador Principal: MARÍA JOSÉ ESCRIBÁ PÉREZ
PI19/00577 . INSTITUTO DE SALUD CARLOS III . 2020
Contrato PFIS: Predoctorales de formación en investigación en salud. Elena Juarez
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
FI19/00110 . INSTITUTO DE SALUD CARLOS III . 2020
ESTUDIO CLÍNICO PILOTO PARA EVALUAR EL EFECTO DE LA VITAMINA D SOBRE EL TAMAÑO DE LOS MIOMAS EN MUJERES CON DEFICIENCIA DE VITAMINA D.
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
IIS-COL-2018-01 . 2019
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.
Investigador Principal: VICENTE PAYÁ AMATE
M12-671
IMPACTO DE LA INFECCIÓN POR SARS-COV-2 (COVID-19) EN EL ENDOMETRIO HUMANO: EVALUACIÓN IN VITRO DE LOS EFECTOS DE HIDROXICLOROQUINA (HCQ) UTILIZANDO ORGANOIDES ENDOMETRIALES HUMANOS.
Investigador Principal: IRENE CERVELLÓ ALCARAZ
2020-268-1_CRC FERRING COVID_CERVELLO . FERRING PHARMACEUTICALS A/S . 2020
Efecto de la Vitamina D y los Disruptores Endocrinos sobre la Longitud Telomérica en Células del Cúmulo y los Resultados Reproductivos.
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
PI21/00310 . INSTITUTO DE SALUD CARLOS III . 2022
Influencia del virus del papiloma humano (VPH) en semen sobre los resultados reproductivos y lavado de semen con heparinasa como opción terapéutica en la infección.
Investigador Principal: NICOLÁS GARRIDO PUCHALT
PI21/00322 . INSTITUTO DE SALUD CARLOS III . 2022
PREPARACION DE FOLICULOS ANTRALES, PREVIA A FECUNDACION IN VITRO TIPO ICSI, EN PACIENTES CON BAJA RESPUESTA OVARICA. ENSAYO CLINICO PROSPECTIVO ALEATORIZADO CONTROLADO.
Investigador Principal: CÉSAR DÍAZ GARCÍA
FOLLPRIM
IMPACT OF SERUM PROGESTERONE CONCENTRATION ON THE DAY OF EMBRYO TRANSFER IN MODIFIED NATURAL CYCLES AND STIMULATED CYCLES ON ONGOING PREGNANCY RATE.
Investigador Principal: MARÍA ELENA LABARTA DEMUR
IVI-PRO-2019-02
PLASMA RICO EN PLAQUETAS PROCEDENTE DE CORDÓN UMBILICAL PARA EL TRATAMIENTO DE PATOLOGÍAS ENDOMETRIALES (ENDOMETRIO FINO/ SÍNDROME DE ASHERMAN/ ATROFIA ENDOMETRIAL): UN ESTUDIO PILOTO.
Investigador Principal: MÓNICA ROMEU VILLARROYA
2001-FIVI-002-IC . 2021
Clonación gamética por generación de partenogenotas humanos
Investigador Principal: MARÍA JOSÉ ESCRIBÁ PÉREZ
PI22/00924 . INSTITUTO DE SALUD CARLOS III . 2023
Estudio de los mecanismos moleculares relacionados con la resistencia a insulina y resistencia a progesterona que influyen en la receptividad endometrial en pacientes con adenomiosis.
Investigador Principal: ANTONIO PELLICER MARTÍNEZ
FPU21/01178 . MINISTERIO DE UNIVERSIDADES . 2022
Estudio transcriptómico y secretómico de embriones euploides y aneuploides desde etapas preimplantacionales hasta etapas postimplantacionales tempranas. . AICO. Francisco Domínguez y Patricia Díaz
Investigador Principal: FRANCISCO DOMÍNGUEZ HERNÁNDEZ
CIAICO/2022/203 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023